The word "revolutionary" sometimes gets thrown around a lot, but it certainly applies to Sarepta Therapeutics (NASDAQ: SRPT). This midcap biotech company has developed several treatments for Duchenne muscular dystrophy (DMD) -- even earning approval for the first gene therapy for the rare genetic illness.

However, none of that has done much to help Sarepta Therapeutics' stock performance this year, as it has severely lagged the broader market. Still, there are excellent reasons to remain optimistic about the company's future. Let's take a look at them.

DMD is a progressive disease that affects patients' muscles. Sarepta currently has four approved products, all targeting this condition. However, the company has encountered several clinical and regulatory issues this year that explain its poor performance.

Continue reading

Source Fool.com